Abstract: A present disclosure includes a) a method for sealing a face mask to a face with a facial cream, b) a method for cleaning a human face having a face mask sealant thereon that includes the step of rubbing the face mask sealant into the face, and c) a face mask sealant composition that is applied between a face mask and a human face.

Abstract: Activated hydrogen peroxide disinfecting compositions are provided especially for low-foaming applications. A concentrate for dilution by an end-user is provided, which includes a hydrogen peroxide source, a non-surfactant organic sulfonic acid or salt thereof, a non-ionic surfactant, and an optional organic acid. Also provided is a ready-to-use hydrogen peroxide, disinfectant solution including a biocidal amount of hydrogen peroxide, a non-surfactant organic sulfonic acid or salt thereof, a non-ionic surfactant, water as solvent and an optional organic acid. An end-user can disinfect a surface of microorganisms by contacting the surface with the disinfecting composition for an amount of time effective to kill a majority of the microbes located on the surface.

Abstract: The present invention relates to a compound having the following formula (I) as well as a method for preparing such a compound, a cosmetic or pharmaceutical composition containing such a compound, and the use thereof as a depigmenting, lightening, bleaching or whitening agent and for treating pigmentation disorders, notably by topical application on the skin.

Abstract: Methods of attracting Drosophila suzukii, involving treating an object or area with a Drosophila suzukii attracting effective amount of a composition containing acetoin and at least one compound selected from ethyl octanoate, acetic acid, ethyl acetate, phenethyl alcohol, or mixtures thereof; wherein said composition does not contain ethanol.

Abstract: The invention relates to bola-amphiphilic compounds and their uses for biomedical application. The invention particularly relates to the use of bola-amphiphilic compounds for providing low molecular weight gels (LMWG), useful, in particular, as culture media for animal or human cells, or as biocompatible material for biomedical applications.

Abstract: Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.

Abstract: This invention relates to the use of polycarboxylic acid compounds, aqueous compositions comprising the same, cosmetic compositions comprising the same, in particular, hair care compositions, and their use for the treatment of hair, and a process for the treatment of hair comprising the use of said cosmetic compositions.

Abstract: The present invention relates to orthopedic implants, in particular to hip and knee prostheses, substantially involving metallic substrates with an antibacterial surface treatment consisting of silver immobilized in an organic linker and ligand via a multistep solution dipping and drying process. This treatment while being biocompatible is designed to inhibit bacterial growth and therefore combat periprosthetic infection which is one of the main causes of revision in hip and knee arthroplasty.

Abstract: Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

Abstract: The present disclosure relates to a makeup removing composition comprising: (a) about 5 to about 50 wt. % of exfoliating particles; (b) about 5 to about 30 wt. % of glycerin; (c) about 1 to about 50 wt. % of one or more natural fatty compounds; and (d) about 25 to about 75 wt. % of one or more nonionic surfactants; wherein the weight percentages are based on the total weight of the composition. In addition to effectively removing makeup, the composition both exfoliates and hydrates the skin. Accordingly, the disclosed includes method for removing makeup from the skin and/or methods for exfoliating and hydrating the skin.

Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at least two actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or a derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and Epilobium angustifolium extract.

Abstract: Multifunctional cancer targeting nanoparticles include a magnetic central core including gold coated iron oxide, an outer layer including trimethyl chitosan microspheres and folic acid and a linker between the central core and the outer layer, the linker including cysteamine. An anti-cancer drug can be supported by the outer layer. The multifunctional cancer targeting nanoparticle can provide simultaneous cancer cell diagnosis and therapy. An amount of heat and an amount of the anti-cancer drug released by the nanoparticle can be controlled by application of a magnetic field.

Abstract: According to the invention there is provided inter alia a medical device for delivering a paclitaxel to a tissue, the device the device having a coating layer applied to a surface of the device, the coating layer comprising components i), ii) and iii), wherein component i) is a therapeutic agent which is paclitaxel; and component ii) is urea or a pharmaceutically acceptable salt thereof, or a urea derivative or a pharmaceutically acceptable salt thereof; and component iii) is succinic acid, glutaric acid or caffeine, or a pharmaceutically acceptable salt of any one thereof.

Abstract: The present invention provides a compound represented by formula (I), (in the formula, A1 and A2 each independently represents a carbon atom or a nitrogen atom; X1 represents an unsubstituted or substituted C1-6 alkyl group or the like; n represents an integer of 0 to 4; R1 represents an unsubstituted or substituted C1-6 alkylthio group or the like; B1 and B4 each independently represent a carbon atom, a nitrogen atom or the like; R2 and R3 each independently represent a hydrogen atom, a halogeno group or the like; Ar represents an unsubstituted or substituted C6-10 aryl group or the like) or a salt thereof, and a harmful organism control agent including thereof.

Abstract: The invention relates to compositions containing selenite-containing compounds and pharmaceutically acceptable acids, selected from citric acid, acetic acid, malic acid, carbonic acid, sulphuric acid, nitric acid, hydrochloric acid, fruit acids or mixtures thereof, for use for treating cervical inflammations, dysplasia and/or carcinomas. The invention further relates to methods of using such compositions.

Abstract: The invention describes novel compositions and methods utilized for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include hyperhidrosis, bromhidrosis, and chromhidrosis, One representative composition of the invention comprises; water, alcohol, aluminum sesquichlorohydrate, hydroxypropyl methyl cellulose, polysorbate 20, isopropyl myristate, eucalyptus oil, silicone oil, alkyl benzoate, glycerine, talc, a hydrophillic silica, a hydrophobic silica, phenoxyethanol and ethylhexyl glycerine.

Abstract: A self-integrating hydrogel includes a water-soluble polymer. The water-soluble polymer includes a repeating unit having at least one functional group that includes an oxygen atom, a sulfur atom, or a nitrogen atom, and a pendant chain covalently attached to the oxygen atom, the sulfur atom, or the nitrogen atom of the at least one functional group of the repeating unit. The pendant chain includes ureido-pyrimidinone.

Abstract: Disclosed are a pharmaceutical composition, cosmetic product, and food or drink product each comprising a porous ceramic obtained by combustion synthesis of a starting material comprising (1) titanium and (2) at least one member selected from the group consisting of carbon, boron, nitrogen, and silicon; a pharmaceutical composition and cosmetic product each comprising a radical- and nanobubble-containing liquid; and a blood treatment device comprising a blood flow channel for extracorporeal circulation of a patient's blood, the blood flow channel being provided with the porous ceramic above, and the porous ceramic and the blood are brought into contact with each other.

Abstract: A method of promoting a desired oral microbiota to treat an inflammation condition related to an allergic reaction in a subject in need of such treatment including providing a preformulated edible composition including an amino acid containing ingredient comprising L-arginine, the composition configured to be present as individual molecules of L-arginine within an oral cavity of the subject; removing a biofilm from surfaces within an oral cavity including exposing the biofilm to a biofilm degrading enzyme; wherein during or following removal of the biofilm, the composition is provided contained and at least partially dissolved within an oral cavity of the subject for a period of at least from about 30 seconds to about an hour on a daily basis comprising at least one day to promote an increased concentration of selected oral microbiota, the selected microbiota including Veillonella and Streptococcus.

Abstract: Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.